At the 10th Congress of the European Academy of Neurology (EAN) 2024, Prilenia Therapeutics presented promising results from the additional analyses of Phase II Healey ALS Platform Trial evaluating pridopidine in ALS patients. The positive results will pave the way for the Phase III trial of pridopidine. Developing disease-modifying treatments for amyotrophic lateral sclerosis (ALS)... The post Pridopidine for ALS – promising results appeared first on ACNR ..read more

Effectiveness of cenobamate and vagus nerve stimulation (VNS) highlighted at recent EAN congress At the recent 10th Congress of the European Academy of Neurology (EAN), two investigator-led ePresentation sessions on epilepsy outlined the effectiveness of a combination of anti-seizure medication (ASM) cenobamate and vagus nerve stimulation (VNS) in managing drug-resistant epilepsy (DRE). The combination therapy demonstrated significant improvements in seizure control, highlighting its potential as a safe and effective treatment option, according to GlobalData. Jos Opdenakker, Neurology Analyst ..read more

New AJOVY® (fremanezumab) migraine prevention data presented at the EAN 4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes1 Sub-analysis exploring impact of treatment cessation and reinitiation on migraine prevention suggests potential rise in migraine attacks and diminished treatment effectiveness upon reinitiation1 July 1, 2024: Teva Pharmaceutical Industries Ltd announced new data from ..read more

Twenty years ago, Professor K Ray Chaudhuri and colleagues wrote in ACNR about the often neglected non-motor symptoms of Parkinson’s which impact so much on a patient’s quality of life – symptoms such as pain, poor sleep, depression, anxiety, sexual dysfunction and autonomic problems. Two decades on, the newly launched King’s Parkinson’s Charitable Fund aims to address the huge gaps in patient care which still exist, driven by the patient voice. The charity has been spearheaded by Sir Nicholas Mostyn and Professor Chaudhuri. Sir Nicholas is one of the founder members of Movers & Shakers ..read more

bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. Human astrocytes are key to developing effective in-vitro models of the central nervous system (CNS), enabling the study and testing of new treatments for neurological and neurodegenerative diseases. ioAstrocytes, the newest addition to bit.bio’s ioCells CNS toolkit, are highly characterised and function ..read more

First of four NHS sites roll out head-CT AI to highlight critical head injury scans A new multi-NHS site initiative went live in April, aiming to improve radiology report turnaround times for non-contrast CT head scans by creating prioritised reporting worklists of critical findings. This will allow Emergency Department (ED) clinicians at the Queen Elizabeth University Hospital in Glasgow to make faster decisions about the care, management and discharge of patients with head injuries. The project called ACcEPT (Assess the Clinical Effectiveness in Prioritising CT Heads) commenced at NHS Greate ..read more

23 April 2024: Acadia Pharmaceuticals Inc has announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and can lead to an array of unpredictable symptoms,” said Pamela di Cenzo, Vice President, General Manager, Rare Disease, Canada at Acadia. “If granted marketing authorisation, trofinetide will be the ..read more

Phase II trial will assess efficacy and tolerability of NX210c in Amyotrophic Lateral Sclerosis (ALS) patients 80 patients due to be enrolled with first results expected in early 2026 NX210c drug candidate allows for promising approach to repairing Blood Brain Barrier (BBB) which is impaired in neurodegenerative diseases such as ALS 10 April 2024: Axoltis Pharma, a French biopharmaceutical company dedicated to developing therapeutic solutions for neurodegenerative diseases, today announced the authorisation from ANSM, the French agency for the safety of health products, to launch the SE ..read more

Research Highlights: from American Stroke Association International Stroke Conference, February 2024 Hospital beds for stroke patients are typically elevated at the head, however, a flat head position before surgical removal of a blood clot in the brain (thrombectomy) may lead to better outcomes. Results from a multicentre trial in the U.S. found significant improvements in clinical stability and neurological function for patients with 0-degree head positioning compared to patients with head positioning at a 30-degree angle, suggesting that 0-degree positioning may be an appropriate change to ..read more

Theranica’s REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA Feb. 20, 2024: Theranica, a prescribed digital therapeutics company specialising in neuromodulation devices for migraine and other idiopathic pain conditions, announced the inclusion of its Nerivio Remote Electrical Neuromodulation (REN) wearable, for use in the acute and preventive treatment of migraine, under a commercial coverage policy of Highmark Inc (Highmark). This follows the successful completion of its Coverage with Evidence Development (CED) programme with ..read more